CHICAGO -- Semaglutide further solidified its efficacy for diabetes-associated cardiovascular conditions, this time building ...

The FDA has approved a new drug for a serious heart condition that affects thousands of people. The drug, called Amvuttra ...

ATTR-CM is a disease in which harmful proteins build up in the heart, making it harder to pump blood, according to the ...

A new smart liner called Roliner lets amputees adjust prosthetic fit in real time via smartphone, easing pain and improving ...

Pharmaceuticals announced moderated poster presentations of new data from the HELIOS-B Phase 3 clinical trial, which evaluated ...

Alnylam Pharmaceuticals (NASDAQ:ALNY – Get Free Report) was upgraded by JPMorgan Chase & Co. from a “neutral” rating to an ...

CM, expanding its market reach. JP Morgan upgrades the stock, projecting strong sales and a multi-billion opportunity.

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced moderated poster presentations of new data from the landmark ...

Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY – Get Free Report) has earned a consensus rating of “Moderate Buy” from the twenty ...

Pharmaceuticals highlighted the significance of the FDA approval of Qfitlia, the sixth Alnylam-discovered RNAi therapeutic ...

Top FDA official Peter Marks was forced to resign as the director of the Center for Biologics Evaluation and Research.